Kyverna Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 5.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 350.65M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen...